DAP2 Antibody

What is DAP2 and what are the different proteins associated with this nomenclature?

The term "DAP2" can refer to several distinct proteins in research literature, which is important to clarify when selecting appropriate antibodies:

• DAPK2 (Death-associated protein kinase 2): A calcium/calmodulin-dependent serine/threonine kinase that functions as a positive regulator of apoptosis. DAPK2 belongs to the protein kinase superfamily, CAMK Ser/Thr protein kinase family, and DAP kinase subfamily. It catalyzes ATP-dependent protein phosphorylation reactions .

• Bacteriophage Dap2: A protein encoded by Pseudomonas aeruginosa phage PaoP5 that exhibits dual functionality by binding to bacterial Lon protease (preventing degradation of phage-encoded HNH endonuclease) and disrupting host virulence by sequestering the type III secretion system (T3SS) transcriptional activator ExsA .

• DLGAP2 (Disks large-associated protein 2): A neuronal protein involved in synaptic organization and signaling that is sometimes abbreviated as DAP2 .

Researchers must carefully distinguish between these proteins when selecting antibodies for their experiments and clearly report which specific protein is targeted in their publications.

What applications are DAPK2-specific antibodies validated for?

DAPK2-specific antibodies have been validated for multiple research applications, with specific recommended dilutions:

These applications have been confirmed through both manufacturer testing and independent research publications. When using these antibodies, researchers should perform optimization with their specific samples, as the optimal concentration may be sample-dependent .

What is the molecular weight of DAPK2 and how does this affect antibody detection?

DAPK2 has a calculated molecular weight of 43 kDa, but the observed molecular weight in experimental conditions typically ranges between 38-43 kDa . This variation may result from:

• Post-translational modifications

• Alternative splicing

• Proteolytic processing

• Experimental conditions affecting protein migration

When conducting Western blot analysis, researchers should be aware of this range and not dismiss bands that appear slightly below the calculated molecular weight. Additionally, when validating a new DAPK2 antibody, it's advisable to use positive controls (such as HeLa, A431, or HepG2 cell lysates) where the protein has been previously detected at the expected molecular weight range .

How does bacteriophage Dap2 protein interact with bacterial defense systems, and what implications does this have for antibody-based studies?

Bacteriophage Dap2 protein represents a sophisticated anti-defense system (ADS) that operates through dual mechanisms to ensure phage survival:

• Direct inhibition of Lon protease: Dap2 binds directly to bacterial Lon protease, preventing it from degrading the phage-encoded HNH endonuclease. This interaction is partial when Dap2 acts alone but becomes complete when Dap2 works synergistically with Dap1 .

• Virulence suppression through ExsA sequestration: Dap2 directly binds to ExsA, the master regulator of P. aeruginosa's Type III Secretion System (T3SS), significantly suppressing bacterial pathogenicity .

For antibody-based studies investigating these interactions, researchers must consider:

• Epitope selection: Antibodies targeting Dap2 should be designed to avoid the binding interfaces with either Lon protease or ExsA to prevent interference with natural interactions.

• Functional validation: Beyond detection, antibodies should be validated to ensure they don't disrupt the biological functions of Dap2.

• Cross-reactivity assessment: Due to the evolutionary conservation of Dap2 across 67 identified phage genomes (as of January 2025), antibodies should be tested for specificity against different variants .

This dual functionality makes Dap2 a valuable target for both phage biology studies and potential therapeutic applications, requiring carefully characterized antibodies for research.

What are the challenges in developing specific antibodies against different DAP2 proteins, and how can researchers address epitope selection?

Developing specific antibodies against different DAP2 proteins presents several challenges:

• Nomenclature confusion: The term "DAP2" refers to biologically distinct proteins (DAPK2, phage Dap2, DLGAP2), requiring precise target specification.

• Conservation across species: DAPK2 shares homology between human and mouse forms, making species-specific antibody development challenging. Similarly, bacteriophage Dap2 is conserved across multiple phage types, with 67 sequenced Pseudomonas phages carrying Dap2 homologs with at least 80% identity .

• Functional domain considerations: For DAPK2, antibodies targeting the kinase domain may cross-react with related kinases. For bacteriophage Dap2, antibodies must avoid interfering with functional interaction sites with Lon protease and ExsA.

Addressing epitope selection:

• Use peptide immunogens: Select peptide sequences unique to the specific DAP2 protein. For example, the DAPK2-specific antibody (20048-1-AP) uses a peptide immunogen designed to target DAPK2 specifically .

• Perform comprehensive validation: Beyond the target protein, test against related family members and other DAP2-named proteins.

• Consider recombinant monoclonal approaches: Technologies like the ZooMAb platform (used for Anti-DLGAP2/DAP2 clone 2K11) provide consistent epitope targeting by using recombinant expression in HEK 293 cells .

• Validate functional non-interference: For bacteriophage Dap2 antibodies, confirm they don't disrupt the protein's ability to bind Lon protease or ExsA in functional assays.

How do transcriptomic changes induced by bacteriophage Dap2 impact experimental design when using antibodies to study infected bacterial systems?

The RNA-seq analysis of P. aeruginosa overexpressing Dap2 revealed significant transcriptomic alterations, with 229 differentially expressed genes (93 upregulated, 136 downregulated) . These changes present important considerations for antibody-based studies of infected systems:

• T3SS pathway perturbation: As the most significantly affected pathway, T3SS components show altered expression levels. When using antibodies against T3SS components in Dap2-expressing systems, researchers must account for baseline expression changes rather than attributing all changes to their experimental intervention.

• Temporal expression dynamics: Dap2 transcription peaks at 10 minutes post-infection, while structural genes peak later (30 minutes) . This temporal pattern necessitates time-course analyses when using antibodies to track infection progression.

• Metabolic redirection: Dap2 suppresses virulence pathways while potentially redirecting resources toward phage reproduction. Antibody-based studies of metabolic pathways must account for these Dap2-induced shifts.

Experimental design recommendations:

• Include appropriate controls (vector-only, Dap2-knockout phage, ExsA-knockout bacteria) to disambiguate Dap2-specific effects from other experimental variables .

• Perform parallel RNA and protein analyses, as transcriptomic changes may not perfectly correlate with protein levels due to post-transcriptional regulation.

• Consider the synergistic effects of Dap1/Dap2 co-expression, as their combined presence provides complete protection against Lon protease and may alter experimental outcomes compared to single-protein studies .

What are the optimal storage and handling conditions for DAP2 antibodies to maintain long-term reactivity?

Proper storage and handling of DAP2 antibodies is critical for maintaining their reactivity and specificity. Based on manufacturer recommendations:

For DAPK2-specific antibody (20048-1-AP):

• Storage temperature: Store at -20°C, where it remains stable for one year after shipment.

• Storage buffer: PBS with 0.02% sodium azide and 50% glycerol at pH 7.3.

• Aliquoting: Aliquoting is unnecessary for -20°C storage.

• Special considerations: 20μl sizes contain 0.1% BSA as a stabilizer .

General best practices for all DAP2-related antibodies:

• Avoid repeated freeze-thaw cycles: Even with cryoprotectants like glycerol, repeated freezing and thawing can denature antibodies. If frequent use is anticipated, prepare working aliquots.

• Thawing procedure: Thaw antibodies completely at 4°C or on ice before use, as partial thawing can create concentration gradients.

• Working dilution preparation: Prepare working dilutions immediately before use and discard unused diluted antibody. Diluted antibodies lacking preservatives are susceptible to microbial contamination and degradation.

• Contamination prevention: Use sterile technique when handling antibody vials and avoid touching the rubber stopper with bare hands.

• Transportation: When moving antibodies between facilities, use dry ice for shipping and monitor temperature during transit.

Adhering to these storage and handling guidelines will help ensure consistent antibody performance across experiments and extend the useful life of these research reagents.

What validation strategies should researchers employ to confirm the specificity of DAP2 antibodies in their experimental systems?

A comprehensive validation strategy for DAP2 antibodies should include multiple approaches to confirm specificity:

• Positive and negative controls:

  • For DAPK2: Use HeLa, A431, or HepG2 cell lysates as positive controls based on validated detection .

  • For phage Dap2: Compare wild-type PaoP5 phage with PaoP5ΔDap2 knockout .

  • For DLGAP2/DAP2: Use Raji cell lysate as a positive control based on manufacturer validation .

  • Include knockout/knockdown systems where the target protein is absent or reduced.

• Multiple detection methods:

  • Cross-validate across different applications (WB, IF/ICC, IHC) to ensure consistent detection.

  • For DAPK2 antibodies, compare results using the recommended dilutions: WB (1:1000-1:5000) and IF/ICC (1:10-1:100) .

• Molecular weight verification:

  • DAPK2: Confirm band appearance in the 38-43 kDa range .

  • For other DAP2 proteins, verify against their predicted molecular weights.

• Peptide competition assay:

  • Pre-incubate the antibody with the immunizing peptide, which should abolish specific binding.

• Orthogonal antibody comparison:

  • Test multiple antibodies targeting different epitopes of the same protein.

  • Compare polyclonal antibodies (like 20048-1-AP for DAPK2) with monoclonal antibodies (like clone 2K11 for DLGAP2/DAP2) .

• Functional correlation:

  • For bacteriophage Dap2, confirm antibody detection correlates with T3SS suppression or Lon protease inhibition phenotypes .

These validation approaches provide robust evidence for antibody specificity and help researchers distinguish between the different DAP2-related proteins in their experimental systems.

How should researchers optimize immunostaining protocols for different DAP2 antibodies considering their unique characteristics?

Optimizing immunostaining protocols for different DAP2 antibodies requires consideration of their specific characteristics and experimental conditions:

For DAPK2-specific antibody (20048-1-AP):

• Dilution optimization: Starting with the recommended range (1:10-1:100 for IF/ICC), perform a dilution series to determine optimal signal-to-noise ratio in your specific cell type .

• Fixation method: Compare paraformaldehyde (4%, 10-15 min) with methanol (-20°C, 10 min) fixation, as DAPK2 detection may be sensitive to epitope masking during fixation.

• Permeabilization considerations: Test different permeabilization conditions (0.1-0.5% Triton X-100) as DAPK2 is primarily cytoplasmic but can translocate to different cellular compartments during apoptosis.

• Blocking optimization: Use 5-10% normal serum (matching the species of the secondary antibody) with 1% BSA to reduce background.

For DLGAP2/DAP2 antibody (clone 2K11):

• Antigen retrieval for IHC: Based on manufacturer validation in human kidney and colon tissue sections, heat-mediated antigen retrieval methods should be optimized for DLGAP2/DAP2 detection in paraffin sections .

• Dilution for IHC: Start with the validated 1:100 dilution for paraffin sections and adjust based on staining intensity and background .

For bacteriophage Dap2 detection:

As this is a phage protein expressed in bacterial systems, standard protocols for bacterial immunostaining should be adapted:

• Fixation for bacterial cells: Mild fixation (2% paraformaldehyde, 5-10 min) often preserves phage protein epitopes better than harsh fixation methods.

• Permeabilization for bacterial cells: Lysozyme treatment (10 mg/ml, 15 min) may be required for adequate permeabilization of the bacterial cell wall.

• Detection in phage-infected systems: Consider time-point selection based on the Dap2 expression profile, which peaks at 10 minutes post-infection .

For all DAP2 antibodies, include appropriate controls (primary antibody omission, isotype controls) and consider using tyramide signal amplification systems for weak signals while monitoring background levels.

How can DAP2 antibodies be utilized in studying the synergistic interaction between Dap1 and Dap2 in phage anti-defense systems?

Antibodies against bacteriophage Dap2 provide valuable tools for investigating the newly discovered synergistic interaction between Dap1 and Dap2 in phage anti-defense systems:

• Co-immunoprecipitation (Co-IP) applications:

  • Dap2 antibodies can be used to pull down Dap2 protein complexes from phage-infected bacterial cells to identify and quantify associated proteins including Dap1, Lon protease, and ExsA .

  • Reciprocal Co-IPs with Dap1 antibodies can confirm the interaction and determine stoichiometry.

• Temporal interaction dynamics:

  • Given that Dap2 expression peaks at 10 minutes post-infection , antibodies can track the formation and disassembly of Dap1/Dap2/HNH/Lon complexes over the course of infection through immunofluorescence or proximity ligation assays.

• Structural studies facilitation:

  • Antibodies can aid in protein purification for structural biology approaches (X-ray crystallography, cryo-EM) to visualize the precise binding interfaces between Dap2 and its partners.

  • Epitope-mapped antibodies could be selected to not interfere with complex formation.

• Evolutionary conservation analysis:

  • As Dap1 and Dap2 form a conserved tandem overlapping gene pair across 67 phage genomes , antibodies can be used to assess protein expression and function across diverse phage strains.

  • Cross-reactivity studies with antibodies against different Dap2 variants could reveal evolutionary constraints on functional regions.

• Therapeutic potential assessment:

  • Antibodies could evaluate the therapeutic efficacy of Dap2-expressing phages in animal infection models, correlating Dap2 expression levels with virulence attenuation .

This research area represents a frontier in understanding phage-host interactions, with antibodies serving as critical tools to dissect the molecular mechanisms underlying this sophisticated anti-defense system.

What are the implications of DAPK2's role in apoptosis for cancer research, and how can antibodies facilitate these investigations?

DAPK2 (Death-associated protein kinase 2) functions as a positive regulator of apoptosis , making it a significant target in cancer research with several important implications:

• Tumor suppressor potential:

  • As a pro-apoptotic kinase, DAPK2 may function as a tumor suppressor in certain cancers.

  • DAPK2 antibodies enable researchers to assess protein expression levels across cancer types and correlate with clinical outcomes.

• Therapeutic response biomarker:

  • DAPK2 status may predict response to apoptosis-inducing chemotherapeutics.

  • Immunohistochemical staining with validated antibodies (such as 20048-1-AP at 1:100 dilution) allows screening of patient tumor samples for DAPK2 expression.

• Drug discovery applications:

  • DAPK2 antibodies can be used in high-throughput screening assays to identify compounds that modulate DAPK2 expression or activity.

  • In-cell western techniques using fluorescent secondary antibodies against DAPK2 primary antibodies enable quantitative assessment of drug effects on protein levels.

• Phosphorylation status monitoring:

  • Phospho-specific antibodies against DAPK2 can track its activation state in response to various stimuli.

  • This allows researchers to map signaling pathways connecting external stimuli to apoptotic execution via DAPK2.

• Subcellular localization studies:

  • Immunofluorescence with DAPK2 antibodies (recommended dilution 1:10-1:100) can track protein translocation during apoptosis.

  • Co-staining with organelle markers helps identify regulatory compartmentalization of DAPK2.

The validated detection of DAPK2 in HeLa, A431, and HepG2 cells provides researchers with well-characterized model systems to study this protein's role in cancer biology, with potential translational implications for cancer diagnosis and treatment.

How might advances in antibody engineering impact future research on DAP2-related proteins and their interactions?

Emerging antibody engineering technologies are poised to transform research on DAP2-related proteins through several innovations:

• Single-domain antibodies (nanobodies):

  • These smaller antibody fragments could access previously hidden epitopes in protein complexes like Dap1/Dap2/HNH/Lon .

  • Intracellular expression of anti-Dap2 nanobodies could allow real-time tracking of protein interactions within living bacterial cells during phage infection.

• Bispecific antibodies:

  • Antibodies simultaneously targeting Dap1 and Dap2 could selectively detect the functional complex rather than individual proteins.

  • For DAPK2 research, bispecific antibodies targeting DAPK2 and substrate proteins could identify active signaling complexes.

• Proximity-dependent labeling antibodies:

  • Antibodies conjugated to enzymes like BioID or APEX2 could identify previously unknown interaction partners of DAP2 proteins through proximity-dependent biotinylation.

  • This approach could elucidate the complete interactome of bacteriophage Dap2 or DAPK2 in different cellular contexts.

• Conditionally stable antibodies:

  • Temperature-sensitive or ligand-dependent antibodies could allow controlled detection of DAP2 proteins only under specific experimental conditions.

  • This would enable precise temporal studies of DAPK2 activation during apoptosis or Dap2 function during phage infection cycles.

• In vivo imaging applications:

  • Near-infrared fluorophore-conjugated antibodies against DAPK2 could enable non-invasive imaging of apoptosis in experimental cancer models.

  • For bacteriophage therapy applications, labeled anti-Dap2 antibodies could track phage biodistribution and target engagement in infection models.

These technological advances will not only enhance detection sensitivity and specificity but also expand the repertoire of experimental approaches available for studying the diverse functions of DAP2-related proteins in both basic research and potential therapeutic applications.

What are the most common issues encountered when using DAP2 antibodies, and how can researchers resolve them?

Researchers working with DAP2 antibodies may encounter several common issues that can be systematically addressed:

• Non-specific bands in Western blot:

  • Problem: Additional bands beyond the expected 38-43 kDa range for DAPK2 or specified molecular weights for other DAP2 proteins.

  • Solutions:

    • Optimize blocking conditions (try 5% non-fat dry milk vs. BSA)

    • Increase antibody dilution (start with 1:5000 for WB)

    • Include a peptide competition control

    • Use gradient gels for better resolution of similarly sized proteins

• Weak or absent signal:

  • Problem: Poor detection despite presence of target protein.

  • Solutions:

    • Verify protein extraction method preserves epitope integrity

    • For DAPK2, confirm expression in your cell type (known positive in HeLa, A431, HepG2)

    • For bacteriophage Dap2, check timing of sample collection (peaks at 10 minutes post-infection)

    • Try different antigen retrieval methods for IHC/ICC

    • Increase protein loading or antibody concentration

• High background in immunofluorescence:

  • Problem: Poor signal-to-noise ratio making specific detection difficult.

  • Solutions:

    • Optimize antibody dilution (start with 1:100 for DAPK2)

    • Increase washing steps (duration and number)

    • Use different detergents in wash buffer (Tween-20 vs. Triton X-100)

    • Test alternative blocking agents (normal serum matching secondary antibody species)

    • Ensure secondary antibody is appropriate and properly titrated

• Batch-to-batch variation:

  • Problem: Results differ between antibody lots.

  • Solutions:

    • For critical experiments, purchase sufficient antibody from a single lot

    • Consider recombinant antibodies like the Anti-DLGAP2/DAP2 ZooMAb which offer greater consistency

    • Validate each new lot against previously validated samples

    • Maintain detailed records of lot numbers and performance characteristics

• Cross-reactivity between DAP2 proteins:

  • Problem: Antibody detects multiple DAP2-named proteins.

  • Solutions:

    • Verify antibody specificity using knockout/knockdown controls

    • Select antibodies raised against unique epitopes

    • Perform pre-adsorption with related proteins when possible

    • Use orthogonal detection methods to confirm identity

By implementing these troubleshooting approaches, researchers can improve the reliability and specificity of their DAP2 antibody applications across various experimental systems.